Click here to close now.

SYS-CON MEDIA Authors: JP Morgenthal, AppDynamics Blog, John Wetherill, Harry Trott, Roger Strukhoff

News Feed Item

Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU

NEW YORK, Feb. 12, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU
http://www.reportlinker.com/p02013807/Global-Pharmaceutical--Biotechnology-Outlook-2014-Major-US-and-EU.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Strategy Diversification Divested: Productivity measurements, Divestment of non-core assets resulting in healthy Cash position- Will accelerate Next wave of targeted acquisitionIn the recent years several new therapies have been approved in the area of diabetes (SGLT-2, GLP-1 agonists), Multiple Sclerosis, HCV, melanoma and breast cancer from major pharmaceutical companies. Many of them are expected to reach multibillion dollars peak sales in the near-term which is likely to compensate the patent expiry loss in top-line revenue. Novel mechanisms like anti-PD1, anti-PCSK9 and CDK inhibitors have also got exclusive attention by large cap Pharma companies. Most companies are in race to acquire assets in these hot therapy areas. Companies who already have these assets are investing heavily in clinical development programs. The interest in pursuing opportunities in Oncology therapy is unhindered for all major Pharma companies.

Research investments in oncology likely to continue for several more years due to the significant unmet need exist in this area.But for a few companies, patent expiry impact continues to haunt the top-line and they are finding it difficult to replace declining sales with Proprietary pipeline products. Beyond 2013, the impact of patent loss will further aggravate the revenue decline. They have chosen strategies of prioritization pipeline assets, cost efficiency measures, divestment of non-core assets which yield poor margins and increase focus on therapy areas where they have already proven its mettle. Increase in dividend payout and share repurchase are some near term measures where they are actively participating. Gain in financial strength through divestment of non-core assets (OTC, Animal Health, Consumer health, Diagnostics) will be utilized in pursuing opportunities in high margin therapy areas. At the same time it has becoming more difficult to find such lucrative assets because they are scarce and if available are trading at very high premium in speculation of getting acquired (ex. Roche-Alexion).

Going forward, Economies of Scale will also play a major role in swapping the non-core business among major pharma including Vaccines, OTC and animal health to improve margins.Global Pharma continues to remain attractive due to management efforts on the restructuring of entire business model, cost efficiency measures, de-consolidation, acquisition of high value targeted assets, share repurchase program and dividend policy.Global Biopharmaceutical Outlook 2014-Global Pharma, released by MP Advisors provides analyses of individual large cap companies, promising drug candidates in their late stage pipelines, competitive landscape, and important therapy areas where new innovation will create leadership, forecast for major marketed drugs where competition/ regulatory scenario will change the dynamics, and the potential impact of several important upcoming milestones on the industry

Table of contents

Macro Analysis: Strategy Diversification Divested: Productivity measurements, Divestment of non-core assets resulting in healthy cash position- Will accelerate Next wave of Targeted Acquisitions

• New Drug Filing Declining but compensated by faster approval with Break through Designation
• FDA Break through designation allowed faster market reach
• R&D strategy re-defined- More focus on early development to improve late stage success
• Recent Restructuring efforts of Major Pharma companies
• Cost efficiency measures and divestments
• Financial Environment favourable for the Next Wave of acquisition

Table 1: Pharma Pipeline allocation changes: 2010-2013
Table 2: Global Pharma –Head count reduction & Share repurchase program
Table 3. Cash, Debt and Mkt Cap Of Global Pharma/ Biotech Companies
Table 4: Cash, Debt and EV of Rising star companies
Chart 1: Cash and Debt of Global Pharma/ Biotech Companies

Company Analysis:
1. AstraZeneca: Early Stage Pipeline Strong; Bold Initiatives Offer Some Relief But Are Not Enough To Hold Pressure
• Long term clinical studies and R&D outlook
• Strengthening business in diabetes: Acquisition from BMY
• Outlook of respiratory franchise going forward: Symbicort and PT003
• Brilinta/Brilique –Prescription Trend and formulary adoption improving but not re?ected in revenues
• The impact of competition on Faslodex
• Late stage development program update:
i) Selumitinib
ii) Lesinurad
iii) Olaparib
iv) Benralizumab
v) Brodalumab
vi) Moxetumomab
vii) Trolokinumab
viii) MEDI4736 (anti-PDL1)
ix) AMP-514
• Key Milestone Table

Table 1: PhIIb combo data of lesinurad in gout pts – allopurinol-inadequate responders
Table 2: Recent acquisition /partnership deals done in 2013
Table 3: Generic exposure thru 2018
Chart 1: Chinese market growth: Global Pharma in 2013

2. Bristol-Myers Squibb: Specialty Biopharma with Oncology Focus Can Give Returns: Nivolumab and Eliquis Success Important

• Snapshots Review on Late stage pipeline assets
• Divestment of diabetes business to AZN – Deal review
• Eliquis Ramp up would be central to BMY's stock price performance in 2014
• Yervoy's potential could be limited by emerging competition
• Ipilimumab status in other indications
• Anti-PD1 antibody (Nivolumab, BMS-936558, PhIII) Immunotherapy (NSCLC, Melanoma)
• Other key Pipeline assets: Elotuzumab
• Impact of generization in topline revenue
• Key Milestones

Table: 1: Anti PD-1 pipeline molecules
Table 2: Ongoing PhIII clinical studies on Anti-PD1
Table 3: Peak sale potential of future blockbusters
Table: 4: Generic exposure thru 2018

3. Eli Lilly: Patent Pressures Aggravated With Undifferentiated Pipeline Assets but
Supporting Diabetes Market Offers a sigh of Relief
• Necitumumab offers sigh of relief but commercial signi?cance limited
• Late Stage Assets Review: PEG-Lispro, LY2963016, Dulaglutide, Empagliflozin, SGLT2 + DPP4 FDC, Solanezumab, Baricitinib, Ixekizumab, Cixutumumab, Ramucirumab
• Litigation of marketed products update: Evista and Alimta
• Key milestones
Table: 1: Competitive landscape – GLP-1 agonist
Table 2: SGLT2 inhibitors- competitive landscape
Table 3: Ongoing PhIII clinical studies of Ramucirumab
Table 4: Patent expiry impact through 2018

4. GlaxoSmithKline: Base Business Provides Sustainability; Several Block Buster's Will Offer Growth!
• Multiple blockbusters emerging in Melanoma, Respiratory and HIV
• MAGE-A3 vaccine in NSCLC
• Anoro (Umeclidinium/Vilanterol, LABA/LAMA FDC-Ellipta device) positioning becomes stronger than LABA+ICS or LABA or LAMA mono in COPD
• Relvar/Breo Ellipta (Vilanterol/Fluticasone FDC): Efficacy and safety data in Asthma and COPD
• Eperzan (Albiglutide): Superior ef?cacy, better tolerability, ease of administration and compliance bene?ts should position Albiglutide better than competition in earlier lines of treatment
• Key Milestones

Table 1: Clinical data of BRAF Inhibitor in Metastatic Melanoma
Table 2: Bydureon, Albiglutide & Victoza- DURATION 6 vs. HARMONY 6, 7

5. Merck: Restructuring Impact And Targeted Focus On Oncology And HCV Will Drive Growth!!
• Detailed data on Odanacatib – Upside lies in the safety pro?les of this drug
• Completion of Mega-trials should ensure R&D cost savings to the tune of $1billion
• R&D Pipeline Update: HCV combo, Lambrolizumab and Corporate Restructuring Program
• Growing evidence base on CV safety of DPP-IV inhibitors
• TECOS should help DPP-IV expand their share in a fast growing but highly genericized diabetes market
• Once weekly DPP-IV - MK-3102 should help Merck carve a share in the ?rst line setting in type 2 diabetes
• HCV Therapy: MK-5172 and MK-8742 combo, Once daily
• Lambrolizumab (MK-3475, anti-PD1) in Second-line NSCLC; Potential additional Indications for anti-PD1
• Merck restructuring Impact going forward is positive for Investor
• Januvia franchise - Reason for de-growth in the US and outlook for the DPP-IV market –Emerging competition from SGLP-2 inhibitors
• Impact of Gardasil and V503: JP Govt. scheduled to review the withheld decision of Gardasil in early 2014
• View on Remicade Biosimilar approval in Europe
• Key Milestone

Table 1: Ongoing clinical trials of Lambrolizumab
Table 2: Competitive landscape of anti-PD1
Chart 1: Late stage pipeline in HCV therapy

6. Pfizer: Dependent on Palbociclib and Prevnar-13 in Adults to Sustain Business!
• Restructuring: Three Major Business Segments
• Xeljanz (tofacitinib)-RA broader label but slower uptake: Limited Opportunity for Xeljanz and forecast $1.2b in peak sales with competition Following
• Prevnar 13 US growth will be driven by approval in adults and outcome of the CAPiTA study data is the key
• Eliquis Superiority claim in Stroke will give an edge over competitor (Peak sales $2.5b)
• Palbociclib (CDK4/6 cell cycle inhibitor, PhIII, ER positive and HER2 negative Breast cancer) - Blockbuster potential -PFE leading the race: Competitors are 1.5 y behind in development
• Dacomitinib (PhIII, secondline NSCLC) –Low potential
• Bococizumab (RN316 (PF-04950615), PCSK9 inhibitor, PhIII, Hypercholesterolemia) –Third entrant will lose its relevance if others succeed
• Advantages and Risks vs. Competitor in anti-PCSK9 area
• Key Milestones

Table 1: Xeljanz: Efficacy comparison with baricitinib
Table 2: Select oral RA drugs in development
Table 3: Ongoing clinical trials: CDK inh.-Palbociclib

7. Novartis: Pipeline Strengthening : De-consolidation Will Provide Targeted Focus
• Respiratory sales ramp to drive sales; Patent expiry pressure immense
• Oncology targeted and cellular therapy approach
• Divestment of blood transfusion unit to Grifols
• String of Pearls- LDK378, Serelaxin followed by breakthrough designation for BYM338 (bimagrumab)
• Gilenya ramp up in Multiple Sclerosis much faster than expected but market ramp up Tec?dera (BiogenIdec) is extraordinary
• SERELAXIN (RLX-030) in Acute Heart Failure – Unmet need would allow an approval-FDA breakthrough designation granted - LCZ696 in chronic heart failure
• Secukinumab in Plaque Psoriasis - Trying To Be Different in a Crowded Space
• Competitive Scenario in Plaque Psoriasis
• PASPORT-Cushings Head to Head Study positive: Sandostatin LAR Replacement ready in active acromegaly
• Signifor/ Pasireotide will penetrate in patients inadequately controlled on Sandostatin. Signifor LAR will take up market share from Sandostatin LAR before the patent expiry in 2017
• Panobinostat in RRMM
• Sandoz growth to be driven by biosimilars and respiratory generics
• Key Milestone Table

Table 1: Competition in Acromegaly
Table 2: PASPORT-Efficacy and safety comparison: Signifor LAR vs. Sandostatin LAR
Table 3: Select late- & mid-stage pipeline: Plaque Psoriasis
Table 4: PhIII Clinical data on Plaque Psoriasis of marketed products

8. Novo Nordisk: GLP-1 and Insulin Market Becoming Too Competitive; Relief Should
Come From Victoza in Obesity
• Novothirteen targets rare, autosomal, niche market
• Competitive pressures on Victoza
• Dulaglutide Phase III data suggests slightly better ef?cacy with once weekly advantage over Victoza
• Levemir under threat from SAN's U300
• Bio-similar insulins impact cannot be neglected
• Liraglutide 3mg obesity regulatory overhang persists
• Regulatory concerns of pancreatitis, thyroid cancer & CV risk for high dose regimen in obesity
• Haemostasis Franchise
• Key Milestone Table

9. Roche: Pricing Power With Strong Foot Hold In Oncology Will Drive Growth
• Strong late stage pipeline will offer potential sustainability and growth
• Superiority of Gazyva against Rituxan in CLL
• Ramp up of Kadcyla in second-line advanced breast cancer patients
• Perjeta -First approved therapy in preoperative, early stage, and ?rst-line HER2 positive breast cancer strengthening its breast cancer franchise
• Further Indication expansion for Perjeta
• RoActemra monotherapy Superior to Humira: ADACTA Study
• Kadcyla: MARIANNE, EMILIA AND APHINITY trials will lend sustainable growth to breast cancer franchise
• Roche to retain all of its current Herceptin sales beyond Patent Expiry in US and EU; Rituxan Biosimilar threat is negligible
• Etrolizumab ( Ulcerative colitis and Crohn's Disease)
• Avastin outlook - 2014 onwards
• Bitopertin (Schizophrenia-negative symptoms)
• Onartuzumab (MetMab, MET positive NSCLC (2nd and 3rd line) and triple negative
• breast cancer)
• Zelboraf ramp up to get impacted by competition from GSK
• MPDL3280A (anti-PDL1 mAB, PhIII, NSCLC, Melanoma)
• Key Milestone Table

Table 1: Major pipeline molecules with expected filing
Table 2: Efficacy and safety comparison of Kadcyla vs. trastuzumab+docetaxel in ?rstline BC (PhII)
Table 3: Ongoing important clinical studies of Kadcyla in late stage HER 2 positive cancer
Table 4: Ongoing clinical trials on biosimilar rituxan
Table 5: Efficacy target profile of Gazyva in clinical studies
Table 6: Clinical data of BRAF inhibitor in metastatic melanoma

10. Sanofi: Sustainable Business but Innovative Pipeline Not Impressive
• R&D Pipeline: Upside limited due to Strong Competition; but orphan indication approval to improve the top-line growth
• Anti-PCSK9 antibody and Dengue Vaccine are potential mega blockbuster candidates, and could make all the difference for SAN's investor but it will take long to deliver
• Lemtrada ramp up in Europe (CR received in the US)
• Lyxumia (Lixisenatide) –US ?ling withdrawn due to want of CV outcome data from FDA and ELIXA outcome and head to head Victoza data
• New Lantus formulation (Insulin U300)
• Lantus/Lixisenatide combination update
• Patent Expiry Impact to continue in 2014
• Aubagio: Except for oral administration and lower discontinuations, there is no differentiation for Aubagio vs. existing treatment options
• Sarilumab ( anti-IL-6R mAB, Rheumatoid arthritis)
• Dengue Vaccine (PhIII)
• Alirocumab anti-PCSK6, Hypercholesterolemia) –CV outcome study will push the ?ling in 2018
• Key Milestone

Table 1: Sarilumab ACR results at week 24
Table 2: Alicromumab PhIII ODYSSY Program

Annexure I: Clinical and Regulatory Milestones In 2014
Annexure II: Global Pharma- PhII and PhIII Pipeline Candidates
Annexure III: Pipeline Peak Sale Potential Thru 2018
Annexure IV: Impact of Patent Expiry Thro 2018
Annexure V: Drugs Losing Patent Protection By 2018

Companies Mentioned

AstraZeneca,Bristol-Myers Squibb, Eli Lilly, Merck,Novo Nordisk, Novartis, Pfizer, Roche,GlaxoSmithKline

To order this report: Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU
http://www.reportlinker.com/p02013807/Global-Pharmaceutical--Biotechnology-Outlook-2014-Major-US-and-EU.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
From telemedicine to smart cars, digital homes and industrial monitoring, the explosive growth of IoT has created exciting new business opportunities for real time calls and messaging. In his session at @ThingsExpo, Ivelin Ivanov, CEO and Co-Founder of Telestax, shared some of the new revenue sources that IoT created for Restcomm – the open source telephony platform from Telestax. Ivelin Ivanov is a technology entrepreneur who founded Mobicents, an Open Source VoIP Platform, to help create, de...
The Internet of Things (IoT) promises to evolve the way the world does business; however, understanding how to apply it to your company can be a mystery. Most people struggle with understanding the potential business uses or tend to get caught up in the technology, resulting in solutions that fail to meet even minimum business goals. In his session at @ThingsExpo, Jesse Shiah, CEO / President / Co-Founder of AgilePoint Inc., showed what is needed to leverage the IoT to transform your business. ...
Grow your business with enterprise wearable apps using SAP Platforms and Google Glass. SAP and Google just launched the SAP and Google Glass Challenge, an opportunity for you to innovate and develop the best Enterprise Wearable App using SAP Platforms and Google Glass and gain valuable market exposure. In his session at @ThingsExpo, Brian McPhail, Senior Director of Business Development, ISVs & Digital Commerce at SAP, outlined the timeline of the SAP Google Glass Challenge and the opportunity...
As enterprises look to take advantage of the cloud, they need to understand the importance of safeguarding their confidential and sensitive data in cloud environments. Enterprises must protect their data from (i) system administrators who don't need to see the data in the clear and (ii) adversaries who become system administrators from stolen credentials. In short, enterprises must take control of their data: The best way to do this is by using advanced encryption, centralized key management and...
What are the benefits of using an enterprise-grade orchestration platform? In their session at 15th Cloud Expo, Nate Gordon, Director of Technology at Appcore, and Kedar Poduri, Senior Director of Product Management at Citrix Systems, took a closer look at the architectural design factors needed to support diverse workloads and how to run these workloads efficiently as a service provider. They also discussed how to deploy private cloud environments in 15 minutes or less.
In his session at DevOps Summit, Andrei Yurkevich, CTO at Altoros, provided an overview of all the benefits and opportunities, as well as drawbacks of deploying Cloud Foundry PaaS with Juju and compared it to BOSH. Discover the features that overlap, and understand what Juju Charm is, what it is not, where you use one or the other or where you use both BOSH and Juju Charms together. Andrei Yurkevich is Cloud Foundry protagonist and CTO at Altoros. Under his supervision, the Altoros engineering ...
Cultural, regulatory, environmental, political and economic (CREPE) conditions over the past decade are creating cross-industry solution spaces that require processes and technologies from both the Internet of Things (IoT), and Data Management and Analytics (DMA). These solution spaces are evolving into Sensor Analytics Ecosystems (SAE) that represent significant new opportunities for organizations of all types. Public Utilities throughout the world, providing electricity, natural gas and water,...
The Internet of Things will put IT to its ultimate test by creating infinite new opportunities to digitize products and services, generate and analyze new data to improve customer satisfaction, and discover new ways to gain a competitive advantage across nearly every industry. In order to help corporate business units to capitalize on the rapidly evolving IoT opportunities, IT must stand up to a new set of challenges. In his session at @ThingsExpo, Jeff Kaplan, Managing Director of THINKstrateg...
For better or worse, DevOps has gone mainstream. All doubt was removed when IBM and HP threw up their respective DevOps microsites. Where are we on the hype cycle? It's hard to say for sure but there's a feeling we're heading for the "Peak of Inflated Expectations." What does this mean for the enterprise? Should they avoid DevOps? Definitely not. Should they be cautious though? Absolutely. The truth is that DevOps and the enterprise are at best strange bedfellows. The movement has its roots in t...
Can call centers hang up the phones for good? Intuitive Solutions did. WebRTC enabled this contact center provider to eliminate antiquated telephony and desktop phone infrastructure with a pure web-based solution, allowing them to expand beyond brick-and-mortar confines to a home-based agent model. It also ensured scalability and better service for customers, including MUY! Companies, one of the country's largest franchise restaurant companies with 232 Pizza Hut locations. This is one example of...
The true value of the Internet of Things (IoT) lies not just in the data, but through the services that protect the data, perform the analysis and present findings in a usable way. With many IoT elements rooted in traditional IT components, Big Data and IoT isn’t just a play for enterprise. In fact, the IoT presents SMBs with the prospect of launching entirely new activities and exploring innovative areas. CompTIA research identifies several areas where IoT is expected to have the greatest impac...
One of the biggest challenges when developing connected devices is identifying user value and delivering it through successful user experiences. In his session at Internet of @ThingsExpo, Mike Kuniavsky, Principal Scientist, Innovation Services at PARC, described an IoT-specific approach to user experience design that combines approaches from interaction design, industrial design and service design to create experiences that go beyond simple connected gadgets to create lasting, multi-device exp...
There is little doubt that Big Data solutions will have an increasing role in the Enterprise IT mainstream over time. 8th International Big Data Expo, co-located with 17th International Cloud Expo - to be held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA - has announced its Call for Papers is open. As advanced data storage, access and analytics technologies aimed at handling high-volume and/or fast moving data all move center stage, aided by the cloud computing bo...
Some developers believe that monitoring is a function of the operations team. Some operations teams firmly believe that monitoring the systems they maintain is sufficient to run the business successfully. Most of them are wrong. The complexity of today's applications have gone far and beyond the capabilities of "traditional" system-level monitoring tools and approaches and requires much broader knowledge of business and applications as a whole. The goal of DevOps is to connect all aspects of app...
DevOps is the hottest moving target when it comes to software development methodologies. Many people fear that this fast-paced, barrier-breaking movement will leave information security best practices in the dust. Analysts provide recommendations to security professionals using bingo-laden terms like "moving security to the left" or "get a seat at the table." What we need are real-world examples and tactics for security practitioners to be part of DevOps. In his session at DevOps Summit, Andrew...